MX366832B - Composiciones de farmaco de liberacion sostenida convenientemente implantables. - Google Patents

Composiciones de farmaco de liberacion sostenida convenientemente implantables.

Info

Publication number
MX366832B
MX366832B MX2016016614A MX2016016614A MX366832B MX 366832 B MX366832 B MX 366832B MX 2016016614 A MX2016016614 A MX 2016016614A MX 2016016614 A MX2016016614 A MX 2016016614A MX 366832 B MX366832 B MX 366832B
Authority
MX
Mexico
Prior art keywords
sustained release
release drug
drug compositions
implantable sustained
conveniently
Prior art date
Application number
MX2016016614A
Other languages
English (en)
Spanish (es)
Inventor
Vernon Wong
Louis Wood
Original Assignee
Ramscor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor Inc filed Critical Ramscor Inc
Publication of MX366832B publication Critical patent/MX366832B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oral & Maxillofacial Surgery (AREA)
MX2016016614A 2004-10-01 2005-09-27 Composiciones de farmaco de liberacion sostenida convenientemente implantables. MX366832B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61448404P 2004-10-01 2004-10-01
US70966505P 2005-08-19 2005-08-19
PCT/US2005/034822 WO2006039336A2 (en) 2004-10-01 2005-09-27 Conveniently implantable sustained release drug compositions

Publications (1)

Publication Number Publication Date
MX366832B true MX366832B (es) 2019-07-24

Family

ID=36143017

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016016614A MX366832B (es) 2004-10-01 2005-09-27 Composiciones de farmaco de liberacion sostenida convenientemente implantables.
MX2011005101A MX344532B (es) 2004-10-01 2005-09-27 Composiciones de farmaco de liberacion sostenida convenientemente implantables.
MX2007003968A MX2007003968A (es) 2004-10-01 2005-09-27 Composiciones de farmaco de liberacion sostenida convenientemente implantables.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2011005101A MX344532B (es) 2004-10-01 2005-09-27 Composiciones de farmaco de liberacion sostenida convenientemente implantables.
MX2007003968A MX2007003968A (es) 2004-10-01 2005-09-27 Composiciones de farmaco de liberacion sostenida convenientemente implantables.

Country Status (12)

Country Link
US (1) US7906136B2 (enExample)
EP (3) EP3173072A1 (enExample)
JP (6) JP5682991B2 (enExample)
KR (2) KR101341359B1 (enExample)
CN (2) CN101060831B (enExample)
AU (2) AU2005292145C1 (enExample)
BR (1) BRPI0516830A (enExample)
CA (1) CA2582096C (enExample)
MX (3) MX366832B (enExample)
MY (1) MY167123A (enExample)
NZ (1) NZ554426A (enExample)
WO (1) WO2006039336A2 (enExample)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850282B1 (fr) 2003-01-27 2007-04-06 Jerome Asius Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
KR101341359B1 (ko) * 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
EP2329838A3 (fr) * 2004-11-22 2013-02-13 Centre National de la Recherche Scientifique Nétrine 4 mutée, ses fragments et leur utilisation comme médicaments
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1853259A1 (en) 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
WO2007019427A2 (en) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
WO2007076462A2 (en) * 2005-12-22 2007-07-05 Oakwood Laboratories, Llc Sublimable sustained release delivery system and method of making same
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
JP5367692B2 (ja) 2006-02-08 2013-12-11 タイレックス・インコーポレイテッド 一時的補剛メッシュ補綴具
US8591531B2 (en) 2006-02-08 2013-11-26 Tyrx, Inc. Mesh pouches for implantable medical devices
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20090140212A1 (en) * 2006-02-24 2009-06-04 Friedman Joel M Electron Transfer Through Glassy Matrices
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP1864667B1 (en) * 2006-06-01 2013-09-04 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
RU2009110257A (ru) * 2006-08-23 2010-09-27 Новартис АГ (CH) Применение ингибиторов ркс, прежде всего производных индолилмалеимида для лечения глазных заболеваний
US8821943B2 (en) * 2006-09-12 2014-09-02 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US20080138350A1 (en) * 2006-10-20 2008-06-12 Bennett Michael D Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery
CA2667890C (en) * 2006-10-31 2015-01-27 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
AU2007335406B2 (en) 2006-12-18 2012-09-13 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
KR20090118999A (ko) * 2007-03-07 2009-11-18 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
DK2155188T3 (da) * 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9827210B2 (en) * 2007-06-29 2017-11-28 Phovitreal Pty Ltd Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration
KR100882817B1 (ko) * 2007-07-20 2009-02-10 숙명여자대학교산학협력단 보툴리늄 독소를 유효성분으로 포함하는 지방세포 생착증진용 약학적 조성물
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US20110097408A1 (en) * 2007-12-10 2011-04-28 O'malley Bert W Chitosan-based matrices and uses thereof
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
WO2009089845A1 (de) 2008-01-18 2009-07-23 Horst Kief Mittel zur intraartikulären injektion
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20090226547A1 (en) * 2008-03-05 2009-09-10 Gilbard Jeffrey P Dietary Supplement For Eye Health
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9132119B2 (en) * 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
JP5713897B2 (ja) * 2008-07-16 2015-05-07 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 生理活性ペプチドを含有する微粒子を調製するためのプロセス
WO2010011597A2 (en) * 2008-07-22 2010-01-28 Mayo Foundation For Medical Education And Research Treatment of obesity and related disorders
US20110236412A1 (en) * 2008-09-24 2011-09-29 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
US20110212127A1 (en) * 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
WO2010042163A2 (en) * 2008-10-06 2010-04-15 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
JP5731980B2 (ja) 2008-10-09 2015-06-10 ラムズコア， インコーポレイテッド ドライアイ症候群の処置のための組成物および方法
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
SG173167A1 (en) 2009-01-29 2011-08-29 Forsight Labs Llc Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US20120141587A1 (en) * 2009-08-25 2012-06-07 Dale Yoo Compositions and methods for treatment or prevention of post-operative organ or tissue inflammation
EP2462246B1 (en) 2009-09-28 2017-09-06 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US9101607B2 (en) 2010-03-31 2015-08-11 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
CN102892424B (zh) 2010-03-31 2015-04-01 稳定性科技有限公司 病毒颗粒的稳定
EP2552478B1 (en) 2010-03-31 2016-12-21 Stabilitech Ltd. Excipients for stabilising viral particles
DE102010013898A1 (de) * 2010-04-01 2011-10-06 Acino Ag Implantatskanüle mit Implantat und Verfahren zum Befestigen von Implantaten in einer Injektionskanüle
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
JP6111194B2 (ja) 2010-08-05 2017-04-05 フォーサイト・ビジョン フォー・インコーポレーテッド 組み合わせ薬物送達方法および装置
SG187730A1 (en) 2010-08-05 2013-03-28 Forsight Vision 4 Inc Injector apparatus and method for drug delivery
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2012097258A2 (en) * 2011-01-15 2012-07-19 The Regents Of The University Of California Formulations for the prevention and treatment of wolbachia-related disease
ES2543312T3 (es) 2011-02-11 2015-08-18 Batmark Limited Componente para inhalador
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
HRP20192276T1 (hr) * 2011-06-10 2020-05-15 Ramscor, Inc. Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc DISPOSAL OF SMALL MOLECULES THROUGH AN IMPLANTABLE THERAPEUTIC DEVICE
LT2755600T (lt) 2011-09-16 2021-04-26 Forsight Vision4, Inc. Skysčio pakeitimo aparatas
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US20130190839A1 (en) * 2012-01-20 2013-07-25 Jane Rapsey Drug delivery using a sacrificial host
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102310775B1 (ko) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US10688041B2 (en) 2012-05-03 2020-06-23 Kala Pharmaceuticals, Inc. Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US20140105956A1 (en) * 2012-10-11 2014-04-17 Rupak BANERJEE Biodegradable polymer based microimplant for ocular drug delivery
US9555054B2 (en) 2012-11-21 2017-01-31 University Of Louisville Research Foundation, Inc. Compositions and methods for reducing oxidative damage
MX2015008077A (es) 2012-12-21 2015-10-30 Sanofi Sa Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon.
WO2014120866A1 (en) 2013-01-31 2014-08-07 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
AU2014252808A1 (en) * 2013-04-09 2015-11-12 Cresset Biomolecular Discovery Ltd The treatment of inflammatory disorders
KR102245354B1 (ko) * 2013-05-24 2021-04-30 아이콘 바이오사이언스, 인크. 백내장 수술 후 염증에서의 서방출 덱사메타손의 용도
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016011191A1 (en) 2014-07-15 2016-01-21 Forsight Vision4, Inc. Ocular implant delivery device and method
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
ES2835499T3 (es) * 2014-07-30 2021-06-22 Massachusetts Eye & Ear Infirmary Metotrexato para la vitreorretinopatía proliferativa
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
JP2017527611A (ja) * 2014-08-15 2017-09-21 ピクサーバイオ コーポレーション 脊髄損傷を有する患者において炎症を阻害するための組成物、及びそれを使用する方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
WO2016130478A1 (en) 2015-02-09 2016-08-18 University Of Louisville Research Foundation, Inc. Ophthalmic compositions and methods for reducing oxidative damage to an eye lens
WO2016148228A1 (ja) 2015-03-18 2016-09-22 参天製薬株式会社 徐放性医薬組成物
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
CN105496947A (zh) * 2015-11-19 2016-04-20 苏州桓晨医疗科技有限公司 一种药物缓释制剂
MX2018006234A (es) 2015-11-20 2018-08-14 Forsight Vision4 Inc Estructuras porosas para dispositivos de suministro de medicamentos de liberacion prolongada.
CN113017981B (zh) 2016-04-05 2023-07-25 弗赛特影像4股份有限公司 药物递送装置
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2017218284A1 (en) * 2016-06-13 2017-12-21 Massachusetts Eye And Ear Infirmary Local orbital therapy for thyroid eye disease
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
JP7051721B2 (ja) 2016-06-30 2022-04-11 デュレクト コーポレーション デポー製剤
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
TWI773686B (zh) 2016-09-13 2022-08-11 美商愛力根公司 非蛋白梭菌毒素組成物
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
IL275795B2 (en) 2018-01-02 2024-12-01 Armata Pharmaceuticals Inc Medical bacteriophage preparations for the treatment of staphylococcal infection
EP3750487A4 (en) 2018-02-08 2020-12-16 Terumo Kabushiki Kaisha MEDICAL DEVICE AND DEVICE TO PROMOTE ADHESION USER
US11065003B2 (en) 2018-03-19 2021-07-20 Terumo Kabushiki Kaisha Treatment method for joining biological organs
EP3787611A4 (en) 2018-05-01 2022-03-09 Chibi, Inc. LIQUID DEPOT FOR NONINVASIVE DELAYED DELIVERY OF DRUGS TO THE EYE
CN112423740A (zh) 2018-05-01 2021-02-26 奇比有限公司 用于将药物持续递送至视网膜的滴眼剂制剂和方法
WO2020067380A1 (ja) 2018-09-27 2020-04-02 テルモ株式会社 癒合促進デバイスおよび医療デバイス
CN112638288B (zh) 2018-09-27 2024-03-08 泰尔茂株式会社 愈合促进设备
CN113573666A (zh) 2019-03-28 2021-10-29 泰尔茂株式会社 愈合促进器具
JP7410131B2 (ja) 2019-03-28 2024-01-09 テルモ株式会社 癒合促進デバイス
EP3932440A4 (en) 2019-03-28 2022-05-04 TERUMO Kabushiki Kaisha MEDICAL DEVICE
EP3932439A4 (en) 2019-03-28 2022-04-27 TERUMO Kabushiki Kaisha Medical device
EP4028015A4 (en) 2019-09-13 2023-11-15 Aldeyra Therapeutics, Inc. OPHTHALMIC FORMULATIONS OF METHOTREXATE
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
CN113262302B (zh) * 2020-02-17 2022-12-09 湖州惠中济世生物科技有限公司 可注射长效半固体凝胶制剂
AU2021282983A1 (en) * 2020-06-01 2023-02-02 Ads Therapeutics Llc Topical ophthalmological compositions and methods for treating abnormal angiogenesis
HUE070328T2 (hu) * 2020-07-07 2025-05-28 Delsitech Oy Szilíciumdioxid-hidrogél kompozit és alkalmazása
FI20215186A1 (en) * 2021-02-19 2022-08-20 Rebio Tech Oy Compositions for ophthalmic treatment
US11197819B1 (en) * 2021-04-09 2021-12-14 Drug Delivery Company, Llc Extended release bioabsorbable subcutaneous medicinal dosage delivery implant system
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
EP4378493A4 (en) 2021-09-03 2024-11-27 TERUMO Kabushiki Kaisha MEDICAL ELEMENT
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11974979B2 (en) 2022-01-29 2024-05-07 Resurge Therapeutics, Inc. Treatments for benign prostatic hyperplasia
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders
CN118388331B (zh) * 2024-05-07 2025-05-16 山东极地医药科技有限公司 一种羟基丙酮的生产工艺

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3119739A (en) 1961-05-03 1964-01-28 Wanda L Campbell Acetylmethyl-salicylate for pain relief
US4126681A (en) 1975-12-08 1978-11-21 The Procter & Gamble Company Topical composition containing acetyl salicylic acid
US4096271A (en) * 1977-08-03 1978-06-20 American Cyanamid Company Slow release injectable formulations of tetramisole and derivatives in benzyl benzoate
US4244948A (en) 1979-05-07 1981-01-13 Allergan Pharmaceuticals, Inc. Medical use of esters of acetylsalicylic acid to treat acne
US4568547A (en) * 1979-08-30 1986-02-04 Herschler R J Solid pharmaceutical compositions comprising MSM and their production
US4309996A (en) * 1980-04-28 1982-01-12 Alza Corporation System with microporous releasing diffusor
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4454122A (en) 1981-04-27 1984-06-12 Bioresearch S.R.L. Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
AU653325B2 (en) * 1990-02-12 1994-09-29 Lucky Limited A composition durably releasing bioactive polypeptides
US5620700A (en) * 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
JP3220331B2 (ja) 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) * 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
SE9403160D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab Method and means for prevention and treatment of secondary cataract
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2275587C (en) * 1996-12-20 2006-10-24 Alza Corporation Injectable depot gel composition and method of preparing the composition
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6733767B2 (en) * 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US6214838B1 (en) * 1998-06-15 2001-04-10 Takeda Chemical Industries, Ltd. Thienodipyridine derivatives, production and use thereof
ID28460A (id) * 1998-07-08 2001-05-24 Lipogenics Inc Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol
US6174540B1 (en) * 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
US6537566B1 (en) * 1999-03-11 2003-03-25 John Alton Copland Compositions and methods for the non-invasive treatment of uterine fibroid cells
CA2366884A1 (en) * 1999-04-02 2000-10-12 Washington State University Research Foundation Enhanced tissue and subcellular delivery of vitamin e compounds
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
JP2003500368A (ja) 1999-05-24 2003-01-07 ソーナス ファーマシューティカルス，インコーポレイテッド 溶解度が不十分な薬剤のためのエマルジョンビヒクル
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
WO2001070210A2 (en) 2000-03-17 2001-09-27 Avocet Polymer Technologies, Inc. Methods for improving size and appearance of a wound
KR100365678B1 (ko) * 2000-03-24 2002-12-26 주식회사 엘지생명과학 주사능이 개선된 소마토트로핀 조성물
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ATE311201T1 (de) * 2000-08-23 2005-12-15 Akzo Nobel Nv Testosteron-ester formulierung zur anwendung am menschen
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
ATE306951T1 (de) * 2000-11-29 2005-11-15 Allergan Inc Verhinderung von transplantatabstossung im auge
US20040097565A1 (en) * 2001-01-29 2004-05-20 Terashita Zen-Ichi Analgesic and antiinflammatory drugs
US6653992B1 (en) * 2001-02-28 2003-11-25 Varian Medical Systems, Inc. Method and circuit for reduction of correlated noise
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US6960346B2 (en) * 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
EP1531827A4 (en) * 2002-05-24 2009-07-08 Univ Michigan COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES
ATE419831T1 (de) * 2002-07-31 2009-01-15 Alza Corp Injizierbare multimodale polymere depotzusammensetzungen und ihre verwendungen
US7534241B2 (en) * 2002-09-23 2009-05-19 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
WO2004028477A2 (en) * 2002-09-29 2004-04-08 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
US6653288B1 (en) * 2002-09-30 2003-11-25 Virbac S.A. Injectable anthelmintic compositions and methods for using same
AU2003295409B2 (en) * 2002-11-06 2010-02-11 Durect Corporation Controlled release depot formulations
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7399784B2 (en) * 2002-11-26 2008-07-15 Children's Hospital & Research Center At Oakland Tocopherol and tocotrienol anti-obesity medicaments
AU2003301129A1 (en) * 2002-12-20 2004-07-22 Control Delivery Systems, Inc. Steroid compositions for intraocular use
JP2004256524A (ja) * 2003-02-05 2004-09-16 Santen Pharmaceut Co Ltd ステロイド副作用抑制組成物
AU2004219595A1 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
RU2390331C2 (ru) * 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
KR101492361B1 (ko) * 2004-09-17 2015-02-11 듀렉트 코퍼레이션 바람직하게 ｓａｉｂ와 같은 당 에스테르를 포함하는 지속적인 국소 마취제 조성물
KR101341359B1 (ko) * 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물

Also Published As

Publication number Publication date
WO2006039336A2 (en) 2006-04-13
JP6650479B2 (ja) 2020-02-19
JP2012072196A (ja) 2012-04-12
US7906136B2 (en) 2011-03-15
JP2016199596A (ja) 2016-12-01
EP1793803A2 (en) 2007-06-13
AU2005292145A1 (en) 2006-04-13
MX344532B (es) 2016-12-19
EP3173072A1 (en) 2017-05-31
US20060073182A1 (en) 2006-04-06
JP2014156488A (ja) 2014-08-28
AU2011202288B2 (en) 2013-09-19
JP2018090641A (ja) 2018-06-14
HK1107672A1 (en) 2008-04-11
JP2018135400A (ja) 2018-08-30
KR20130124415A (ko) 2013-11-13
JP5682991B2 (ja) 2015-03-11
MY167123A (en) 2018-08-13
WO2006039336A3 (en) 2006-07-06
MX2007003968A (es) 2008-03-04
AU2005292145C1 (en) 2011-07-21
CN101060831B (zh) 2010-06-23
KR20070083901A (ko) 2007-08-24
JP2008514719A (ja) 2008-05-08
NZ554426A (en) 2010-05-28
AU2011202288A1 (en) 2011-06-09
JP6342716B2 (ja) 2018-06-13
KR101341359B1 (ko) 2013-12-13
KR101506925B1 (ko) 2015-03-30
AU2005292145B2 (en) 2011-02-17
EP1793803A4 (en) 2009-09-23
EP1793803B1 (en) 2012-11-07
CA2582096C (en) 2014-01-07
CN101060831A (zh) 2007-10-24
CN101890167B (zh) 2017-03-01
CN101890167A (zh) 2010-11-24
CA2582096A1 (en) 2006-04-13
EP2452670A1 (en) 2012-05-16
BRPI0516830A (pt) 2008-09-23

Similar Documents

Publication Publication Date Title
MY167123A (en) Conveniently implantable sustained release drug compositions
TW200515919A (en) Bioerodible sustained release drug delivery systems
TNSN08079A1 (en) Pharmaceutical compositions for the treatment of inner ear disorders
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
CY1118179T1 (el) Φαρμακευτικη συνθεση
IS7431A (is) Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða
WO2006023130A3 (en) Biodegradable controlled release bioactive agent delivery device
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
WO2005117919A3 (en) Delayed-setting calcium phosphate pastes
WO2004034975A3 (en) Sustained release profile modification
TW200509998A (en) Controlled release of highly soluble agents
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
TW200642704A (en) Oral drug delivery system and methods of use thereof
MY169854A (en) Conveniently implantable sustained release drug compositions
TW200726472A (en) Conveniently implantable sustained release drug compositions
WO2005011589A3 (en) Drug delivery methods and devices
UA89858C2 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
TWI350752B (en) Pharmaceutical composition for the treatment of connective tissue disease